Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report

Sintilimab is an anti-programmed cell death receptor-1 antibody. The phase III clinical trial ORIENT-12 confirmed the safety of sintilimab combined with pemetrexed/platinum in the treatment of advanced squamous non-small cell lung cancer. Skin reactions are the most commonly reported adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Lye, Ya-lei, Shan, Bin, Jia, Chen-hong, Liu, Jiang, Hou, Juan, Du, Wen-li, Feng, Rui, Liang, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608386/
https://www.ncbi.nlm.nih.gov/pubmed/37853877
http://dx.doi.org/10.5021/ad.21.072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10608386/
https://www.ncbi.nlm.nih.gov/pubmed/37853877
http://dx.doi.org/10.5021/ad.21.072

Ejemplares similares